Company: RPTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103764
Chunk: 52

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 52
---
 award, as determined in good faith by our board of directors. All of the option awards granted as of June 18, 2020 to January 29, 2024 were granted with an exercise price per share that was based on the volume weighted average trading price of our common shares for the five trading days prior to the date of grant. All option awards granted after January 29, 2024 were granted with an exercise price per share that was based on the closing price of our common shares on the date of grant. |

| (3) | This column represents the market value of the common shares underlying the stock awards as of December 31, 2024, based on the closing price of our common shares as reported on Nasdaq, of $1.31 per share. |

| (4) | Twenty-five percent of the common shares subject to this award vested or vest on the first anniversary of the vesting commencement date, and the remaining shares vested or vest in 36 equal monthly installments thereafter, subject to the named executive officer’s continued service through each vesting date. |

| (5) | One-third of the common shares subject to this award vest on each of the first, second and third anniversaries of the vesting commencement date, subject to the named executive officer’s continued service through each vesting date. |

| (6) | Pursuant to the separation agreement entered into in March 2025 in connection with Mr. Segal’s resignation as our President and Chief Executive Officer, the vesting of all of Mr. Segal’s unvested options and RSUs subject to a time-based vesting schedule was accelerated as if Mr. Segal had remained employed for an additional 15 months following the effective date of his resignation from Repare. All of Mr. Segal’s option awards will expire on the 15-month anniversary of the termination of his employment with Repare. |

| (7) | Pursuant to the separation agreement entered into in February 2025 in connection with Dr. Koehler’s departure as our Executive Vice President, Chief Medical Officer, the vesting of all of Dr. Koehler’s unvested options and RSUs subject to a time-based vesting schedule was accelerated, on a prorated basis, as if Dr. Koehler had remained employed for an additional nine months following the effective date of her separation, as if each award vested on a monthly basis without regard to the original vesting schedule. All of Dr. Koehler’s option